Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Aricept Generics Earn Lewy Body Dementia Indications
March 14, 2019
- Fujifilm Going Full Throttle in CDMO Biz with Buyout of Biogen Unit
March 13, 2019
- Urief Authorized Generics Now Available: Daiichi Sankyo Espha
March 13, 2019
- FDA Accepts NDA for Insomnia Med Lemborexant, Target Date Set for Dec. 27
March 13, 2019
- Vadadustat Demonstrates Efficacy, Safety in 4 PIII Studies for Renal Anemia: Mitsubishi Tanabe
March 13, 2019
- Galderma Delivers in PIIb Atopic Dermatitis Study for Nemolizumab, Originated by Chugai
March 12, 2019
- Vimpat Dry Syrup Now Available: Daiichi Sankyo, UCB
March 12, 2019
- BMS, Ono Submit Additional Study Data on Orencia for Prevention of Structural Damage to Joints
March 12, 2019
- Fujifilm Toyama Chemical, Sanwa Kagaku Tie Up for Lantus Biosimilar Promotion
March 12, 2019
- UCB, Otsuka to End Copromotion Deal for E Keppra in Japan in 2020
March 12, 2019
- Daiichi Sankyo Espha Launches Authorized Iressa Generic, Introducing AI to Respond to Inquiries
March 12, 2019
- Entyvio Shows Superiority to Humira in PIIIb Study for UC: Takeda
March 12, 2019
- Meiji Pharma Pursuing Low-Cost Strategy to Weather Storm in Generics Space, Overseas Plants Hold Key
March 11, 2019
- Japan Ethical Drug Sales Up 3.3% in January: Crecon
March 11, 2019
- CMIC CMO, Aprecia Join Hands for 3D Printing Therapies
March 11, 2019
- Eisai CEO Says “20% ROE in 2025” within Reach If All 3 Alzheimer’s Candidates, Lenvima Deliver
March 8, 2019
- Shionogi Bags Japan/Taiwan Rights to Akili’s Digital Medicines for ADHD, Autism
March 8, 2019
- Avastin Top Seller in Japan in February: Encise Snapshot
March 8, 2019
- Mitsubishi Tanabe’s Rupafin Most Promoted Drug in December: Anterio
March 8, 2019
- Eisai Seeks Japan Approval for Insomnia Med Lemborexant
March 8, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…